D-MAV Platform Shows Cross-Viral Activity Against Ebola, Opening New Pandemic Preparedness Program
DCOY sits 17% above its 52-week low of $4.32.
Summary
Decoy's D-MAV candidate demonstrated in vitro activity against wild-type Ebola Zaire and Lassa fever virus, validating the platform's cross-viral fusion inhibition premise. The company is opening an exploratory filovirus program targeting Ebola and Marburg, expanding beyond its respiratory focus. This follows a going concern warning and recent financing efforts, adding a new, high-impact pipeline asset that could attract non-dilutive funding or partnerships. The result supports the platform's broad potential and may strengthen the investment thesis ahead of the September 14 special meeting to approve warrant exercises.
At the time of this announcement, DCOY was trading at $5.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $4.32 to $415.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.